Cargando…
Natural Products-Based Nanoformulations: A New Approach Targeting CSCs to Cancer Therapy
Cancer stem cells (CSCs) lead to the occurrence and progression of cancer due to their strong tumorigenic, self-renewal, and multidirectional differentiation abilities. Existing cancer treatment methods cannot effectively kill or inhibit CSCs but instead enrich them and produce stronger proliferatio...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9482958/ https://www.ncbi.nlm.nih.gov/pubmed/36134202 http://dx.doi.org/10.2147/IJN.S380697 |
_version_ | 1784791566164951040 |
---|---|
author | Liao, Wenhao Li, Yuchen Wang, Jing Zhao, Maoyuan Chen, Nianzhi Zheng, Qiao Wan, Lina Mou, Yu Tang, Jianyuan Wang, Zhilei |
author_facet | Liao, Wenhao Li, Yuchen Wang, Jing Zhao, Maoyuan Chen, Nianzhi Zheng, Qiao Wan, Lina Mou, Yu Tang, Jianyuan Wang, Zhilei |
author_sort | Liao, Wenhao |
collection | PubMed |
description | Cancer stem cells (CSCs) lead to the occurrence and progression of cancer due to their strong tumorigenic, self-renewal, and multidirectional differentiation abilities. Existing cancer treatment methods cannot effectively kill or inhibit CSCs but instead enrich them and produce stronger proliferation, invasion, and metastasis capabilities, resulting in cancer recurrence and treatment resistance, which has become a difficult problem in clinical treatment. Therefore, targeting CSCs may be the most promising approach for comprehensive cancer therapy in the future. A variety of natural products (NP) have significant antitumor effects and have been identified to target and inhibit CSCs. However, pharmacokinetic defects and off-target effects have greatly hindered their clinical translation. NP-based nanoformulations (NPNs) have tremendous potential to overcome the disadvantages of NP against CSCs through site-specific delivery and by improving their pharmacokinetic parameters. In this review, we summarize the recent progress of NPNs targeting CSCs in cancer therapy, looking forward to transforming preclinical research results into clinical applications and bringing new prospects for cancer treatment. |
format | Online Article Text |
id | pubmed-9482958 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-94829582022-09-20 Natural Products-Based Nanoformulations: A New Approach Targeting CSCs to Cancer Therapy Liao, Wenhao Li, Yuchen Wang, Jing Zhao, Maoyuan Chen, Nianzhi Zheng, Qiao Wan, Lina Mou, Yu Tang, Jianyuan Wang, Zhilei Int J Nanomedicine Review Cancer stem cells (CSCs) lead to the occurrence and progression of cancer due to their strong tumorigenic, self-renewal, and multidirectional differentiation abilities. Existing cancer treatment methods cannot effectively kill or inhibit CSCs but instead enrich them and produce stronger proliferation, invasion, and metastasis capabilities, resulting in cancer recurrence and treatment resistance, which has become a difficult problem in clinical treatment. Therefore, targeting CSCs may be the most promising approach for comprehensive cancer therapy in the future. A variety of natural products (NP) have significant antitumor effects and have been identified to target and inhibit CSCs. However, pharmacokinetic defects and off-target effects have greatly hindered their clinical translation. NP-based nanoformulations (NPNs) have tremendous potential to overcome the disadvantages of NP against CSCs through site-specific delivery and by improving their pharmacokinetic parameters. In this review, we summarize the recent progress of NPNs targeting CSCs in cancer therapy, looking forward to transforming preclinical research results into clinical applications and bringing new prospects for cancer treatment. Dove 2022-09-14 /pmc/articles/PMC9482958/ /pubmed/36134202 http://dx.doi.org/10.2147/IJN.S380697 Text en © 2022 Liao et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Review Liao, Wenhao Li, Yuchen Wang, Jing Zhao, Maoyuan Chen, Nianzhi Zheng, Qiao Wan, Lina Mou, Yu Tang, Jianyuan Wang, Zhilei Natural Products-Based Nanoformulations: A New Approach Targeting CSCs to Cancer Therapy |
title | Natural Products-Based Nanoformulations: A New Approach Targeting CSCs to Cancer Therapy |
title_full | Natural Products-Based Nanoformulations: A New Approach Targeting CSCs to Cancer Therapy |
title_fullStr | Natural Products-Based Nanoformulations: A New Approach Targeting CSCs to Cancer Therapy |
title_full_unstemmed | Natural Products-Based Nanoformulations: A New Approach Targeting CSCs to Cancer Therapy |
title_short | Natural Products-Based Nanoformulations: A New Approach Targeting CSCs to Cancer Therapy |
title_sort | natural products-based nanoformulations: a new approach targeting cscs to cancer therapy |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9482958/ https://www.ncbi.nlm.nih.gov/pubmed/36134202 http://dx.doi.org/10.2147/IJN.S380697 |
work_keys_str_mv | AT liaowenhao naturalproductsbasednanoformulationsanewapproachtargetingcscstocancertherapy AT liyuchen naturalproductsbasednanoformulationsanewapproachtargetingcscstocancertherapy AT wangjing naturalproductsbasednanoformulationsanewapproachtargetingcscstocancertherapy AT zhaomaoyuan naturalproductsbasednanoformulationsanewapproachtargetingcscstocancertherapy AT chennianzhi naturalproductsbasednanoformulationsanewapproachtargetingcscstocancertherapy AT zhengqiao naturalproductsbasednanoformulationsanewapproachtargetingcscstocancertherapy AT wanlina naturalproductsbasednanoformulationsanewapproachtargetingcscstocancertherapy AT mouyu naturalproductsbasednanoformulationsanewapproachtargetingcscstocancertherapy AT tangjianyuan naturalproductsbasednanoformulationsanewapproachtargetingcscstocancertherapy AT wangzhilei naturalproductsbasednanoformulationsanewapproachtargetingcscstocancertherapy |